A recent clinical study, the Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) trial,27 reported that CKD patients with DM treated with a nuclear factor-erythroid 2-related factor 2 (Nrf2) activator, bardoxolone methyl, an antioxidant drug which improved eGFR levels in CKD patients,28 unexpectedly developed cardiovascular events, especially hospitalization for heart failure. Here, NFE2L2 is linked to type 2 diabetes mellitus.